{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:12:04Z","timestamp":1788541924993,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,4]],"date-time":"2023-03-04T00:00:00Z","timestamp":1677888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00432-023-04659-5","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T23:24:29Z","timestamp":1677885869000},"page":"7925-7932","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features"],"prefix":"10.1007","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4412-4913","authenticated-orcid":false,"given":"Sara","family":"Esteves-Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6169-7521","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Rosinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,4]]},"reference":[{"issue":"2","key":"4659_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-14-0845","volume":"172","author":"F Albarel","year":"2015","unstructured":"Albarel F, Gaudy C, Castinetti F et al (2015) Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 172(2):195\u2013204. https:\/\/doi.org\/10.1530\/EJE-14-0845","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"4659_CR2","doi-asserted-by":"publisher","first-page":"R107","DOI":"10.1530\/EJE-19-0169","volume":"181","author":"F Albarel","year":"2019","unstructured":"Albarel F, Castinetti F, Brue T (2019) Management of endocrine disease: Immune check point inhibitors-induced hypophysitis. Eur J Endocrinol 181(3):R107\u2013R118. https:\/\/doi.org\/10.1530\/EJE-19-0169","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"4659_CR3","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1007\/s40618-015-0301-z","volume":"38","author":"PB Araujo","year":"2015","unstructured":"Araujo PB, Coelho MCA, Arruda M, Gadelha MR, Neto LV (2015) Ipilimumab-induced hypophysitis: review of the literature. J Endocrinol Invest 38(11):1159\u20131166. https:\/\/doi.org\/10.1007\/s40618-015-0301-z","journal-title":"J Endocrinol Invest"},{"issue":"25","key":"4659_CR4","doi-asserted-by":"publisher","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","volume":"23","author":"P Attia","year":"2005","unstructured":"Attia P, Phan GQ, Maker A et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23(25):6043\u20136053. https:\/\/doi.org\/10.1200\/JCO.2005.06.205","journal-title":"J Clin Oncol"},{"issue":"6","key":"4659_CR5","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/cncr.31200","volume":"124","author":"R Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R, Ott PA, Hodi FS, Kaiser UB, Tolaney SM, Min L (2018) Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management. Cancer 124(6):1111\u20131121. https:\/\/doi.org\/10.1002\/cncr.31200","journal-title":"Cancer"},{"issue":"6","key":"4659_CR6","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","volume":"28","author":"JA Blansfield","year":"2005","unstructured":"Blansfield JA, Beck KE, Tran K et al (2005) Cytotoxic T-Lymphocyte-Associated Antigen-4 Blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28(6):593\u2013598. https:\/\/doi.org\/10.1097\/01.cji.0000178913.41256.06","journal-title":"J Immunother"},{"issue":"17","key":"4659_CR7","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline. J Clin Oncol 36(17):1714\u20131768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"issue":"6","key":"4659_CR8","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1210\/jc.2015-1218","volume":"100","author":"LHA Broersen","year":"2015","unstructured":"Broersen LHA, Pereira AM, J\u00f8rgensen JOL, Dekkers OM (2015) Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis. J Clin Endocrinol Metab 100(6):2171\u20132180. https:\/\/doi.org\/10.1210\/jc.2015-1218","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"4659_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"Byun DJ, Wolchok JD, Rosenberg LM, Girotra M (2017) Cancer immunotherapy \u2014 immune checkpoint blockade and associated endocrinopathies. Nat Rev Endocrinol 13(4):195\u2013207. https:\/\/doi.org\/10.1038\/nrendo.2016.205","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"4659_CR10","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/ERC-18-0320","volume":"26","author":"F Castinetti","year":"2019","unstructured":"Castinetti F, Albarel F, Archambeaud F et al (2019) French endocrine society guidance on endocrine side effects of immunotherapy. Endocr Relat Cancer 26(2):G1\u2013G18. https:\/\/doi.org\/10.1530\/ERC-18-0320","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4659_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"LS Chang","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L (2019) Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev 40(1):17\u201365. https:\/\/doi.org\/10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"issue":"1","key":"4659_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.7861\/clinmed.2022-0429","volume":"23","author":"T Cooksley","year":"2023","unstructured":"Cooksley T, Knight T, Lindsay D et al (2023) Immune checkpoint inhibitor-mediated hypophysitis: no place like home. Clin Med 23(1):81\u201384. https:\/\/doi.org\/10.7861\/clinmed.2022-0429","journal-title":"Clin Med"},{"issue":"2","key":"4659_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ncpendmet1051","volume":"5","author":"KH Darzy","year":"2009","unstructured":"Darzy KH (2009) Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab 5(2):88\u201399. https:\/\/doi.org\/10.1038\/ncpendmet1051","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"03","key":"4659_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1055\/a-0843-3366","volume":"51","author":"J de Filette","year":"2019","unstructured":"de Filette J, Andreescu C, Cools F, Bravenboer B, Velkeniers B (2019) A Systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors. Horm Metab Res 51(03):145\u2013156. https:\/\/doi.org\/10.1055\/a-0843-3366","journal-title":"Horm Metab Res"},{"issue":"3","key":"4659_CR15","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s11102-018-0866-6","volume":"21","author":"SMC de Sousa","year":"2018","unstructured":"de Sousa SMC, Sheriff N, Tran CH et al (2018) Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis. Pituitary 21(3):274\u2013282. https:\/\/doi.org\/10.1007\/s11102-018-0866-6","journal-title":"Pituitary"},{"issue":"12","key":"4659_CR16","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3747\/co.27.5223","volume":"27","author":"K Esfahani","year":"2020","unstructured":"Esfahani K, Roudaia L, Buhlaiga N, del Rincon SV, Papneja N, Miller WH (2020) A Review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol 27(12):87\u201397. https:\/\/doi.org\/10.3747\/co.27.5223","journal-title":"Curr Oncol"},{"issue":"1","key":"4659_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11102-015-0671-4","volume":"19","author":"A Faje","year":"2016","unstructured":"Faje A (2016) Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19(1):82\u201392. https:\/\/doi.org\/10.1007\/s11102-015-0671-4","journal-title":"Pituitary"},{"issue":"11","key":"4659_CR18","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1210\/jc.2014-2306","volume":"99","author":"AT Faje","year":"2014","unstructured":"Faje AT, Sullivan R, Lawrence D et al (2014) Ipilimumab-Induced Hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99(11):4078\u20134085. https:\/\/doi.org\/10.1210\/jc.2014-2306","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"4659_CR19","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1002\/cncr.31629","volume":"124","author":"AT Faje","year":"2018","unstructured":"Faje AT, Lawrence D, Flaherty K et al (2018) High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer 124(18):3706\u20133714. https:\/\/doi.org\/10.1002\/cncr.31629","journal-title":"Cancer"},{"issue":"3","key":"4659_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/EJE-19-0238","volume":"181","author":"A Faje","year":"2019","unstructured":"Faje A, Reynolds K, Zubiri L et al (2019) Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol 181(3):211\u2013219. https:\/\/doi.org\/10.1530\/EJE-19-0238","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"4659_CR21","doi-asserted-by":"publisher","first-page":"000457","DOI":"10.1136\/ESMOOPEN-2018-000457","volume":"4","author":"G Fuc\u00e0","year":"2019","unstructured":"Fuc\u00e0 G, Galli G, Poggi M et al (2019) Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open. 4(1):000457. https:\/\/doi.org\/10.1136\/ESMOOPEN-2018-000457","journal-title":"ESMO Open."},{"issue":"21","key":"4659_CR22","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/jnci\/djr373","volume":"103","author":"OPR Hamnvik","year":"2011","unstructured":"Hamnvik OPR, Larsen PR, Marqusee E (2011) Thyroid dysfunction from antineoplastic agents. JNCI J National Cancer Inst 103(21):1572\u20131587. https:\/\/doi.org\/10.1093\/jnci\/djr373","journal-title":"JNCI J National Cancer Inst"},{"issue":"7","key":"4659_CR23","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EC-18-0068","volume":"7","author":"CE Higham","year":"2018","unstructured":"Higham CE, Olsson-Brown A, Carroll P et al (2018) Society For Endocrinology Endocrine Emergency Guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr Connect 7(7):G1\u2013G7. https:\/\/doi.org\/10.1530\/EC-18-0068","journal-title":"Endocr Connect"},{"issue":"1","key":"4659_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40842-016-0034-8","volume":"2","author":"FA Hypophysitis","year":"2016","unstructured":"Hypophysitis FA (2016) Evaluation and Management. Clin Diabetes Endocrinol 2(1):15. https:\/\/doi.org\/10.1186\/s40842-016-0034-8","journal-title":"Clin Diabetes Endocrinol"},{"issue":"12","key":"4659_CR25","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1007\/s00259-020-04815-w","volume":"47","author":"A Iravani","year":"2020","unstructured":"Iravani A, Osman MM, Weppler AM et al (2020) FDG PET\/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment. Eur J Nucl Med Mol Imaging 47(12):2776\u20132786. https:\/\/doi.org\/10.1007\/s00259-020-04815-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"230","key":"4659_CR26","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1126\/scitranslmed.3008002","volume":"6","author":"S Iwama","year":"2014","unstructured":"Iwama S, de Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P (2014) Pituitary expression of CTLA-4 Mediates hypophysitis secondary to administration of CTLA-4 Blocking antibody. Sci Transl Med. 6(230):332. https:\/\/doi.org\/10.1126\/scitranslmed.3008002","journal-title":"Sci Transl Med."},{"issue":"3","key":"4659_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/cen.13063","volume":"85","author":"MN Joshi","year":"2016","unstructured":"Joshi MN, Whitelaw BC, Palomar MTP, Wu Y, Carroll PV (2016) Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (oxf) 85(3):331\u2013339. https:\/\/doi.org\/10.1111\/cen.13063","journal-title":"Clin Endocrinol (oxf)"},{"key":"4659_CR28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201979","author":"G Kroemer","year":"2021","unstructured":"Kroemer G, Zitvogel L (2021) Immune checkpoint inhibitors. J Exper Med. https:\/\/doi.org\/10.1084\/jem.20201979","journal-title":"J Exper Med"},{"issue":"6204","key":"4659_CR29","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1126\/science.1255904","volume":"345","author":"HS Kuehn","year":"2014","unstructured":"Kuehn HS, Ouyang W, Lo B et al (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345(6204):1623\u20131627. https:\/\/doi.org\/10.1126\/science.1255904","journal-title":"Science"},{"issue":"5","key":"4659_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.crad.2020.12.028","volume":"76","author":"A Lasocki","year":"2021","unstructured":"Lasocki A, Iravani A, Galligan A (2021) The imaging of immunotherapy-related hypophysitis and other pituitary lesions in oncology patients. Clin Radiol 76(5):325\u2013332. https:\/\/doi.org\/10.1016\/j.crad.2020.12.028","journal-title":"Clin Radiol"},{"issue":"1","key":"4659_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/1479-5876-11-108","volume":"11","author":"S Laurent","year":"2013","unstructured":"Laurent S, Queirolo P, Boero S et al (2013) The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-\u03b1 production. J Transl Med 11(1):108. https:\/\/doi.org\/10.1186\/1479-5876-11-108","journal-title":"J Transl Med"},{"issue":"4","key":"4659_CR32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","volume":"29","author":"AV Maker","year":"2006","unstructured":"Maker AV, Yang JC, Sherry RM et al (2006) Intrapatient dose escalation of anti\u2013ctla-4 antibody in patients with metastatic melanoma. J Immun 29(4):455\u2013463. https:\/\/doi.org\/10.1097\/01.cji.0000208259.73167.58","journal-title":"J Immun"},{"issue":"3","key":"4659_CR33","doi-asserted-by":"publisher","first-page":"351","DOI":"10.4158\/EP11273.OR","volume":"18","author":"L Min","year":"2012","unstructured":"Min L, Vaidya A, Becker C (2012) Association of Ipilimumab therapy for advanced melanoma with secondary adrenal insufficiency: a case series. Endocr Pract 18(3):351\u2013355. https:\/\/doi.org\/10.4158\/EP11273.OR","journal-title":"Endocr Pract"},{"issue":"4","key":"4659_CR34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","volume":"21","author":"L Min","year":"2015","unstructured":"Min L, Hodi FS, Giobbie-Hurder A et al (2015) Systemic High-dose corticosteroid treatment does not improve the outcome of Ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21(4):749\u2013755. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2353","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4659_CR35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6(1):38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"issue":"19","key":"4659_CR36","doi-asserted-by":"publisher","first-page":"6140","DOI":"10.1073\/pnas.1417320112","volume":"112","author":"E Romano","year":"2015","unstructured":"Romano E, Kusio-Kobialka M, Foukas PG et al (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci 112(19):6140\u20136145. https:\/\/doi.org\/10.1073\/pnas.1417320112","journal-title":"Proc Natl Acad Sci"},{"issue":"26","key":"4659_CR37","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of Anti\u2013PD-1 antibody in cancer. N Engl J Med 366(26):2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690","journal-title":"N Engl J Med"},{"issue":"2","key":"4659_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey JD, Zhang B (2021) Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J 23(2):39. https:\/\/doi.org\/10.1208\/s12248-021-00574-0","journal-title":"AAPS J"},{"key":"4659_CR39","unstructured":"U.S. Food and Drug Administration. Dorstalimab. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&ApplNo=761174. Accessed 20 Feb 2022."},{"issue":"21","key":"4659_CR40","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","volume":"30","author":"JS Weber","year":"2012","unstructured":"Weber JS, K\u00e4hler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with Ipilimumab. J Clin Oncol 30(21):2691\u20132697. https:\/\/doi.org\/10.1200\/JCO.2012.41.6750","journal-title":"J Clin Oncol"},{"issue":"7","key":"4659_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"Wright JJ, Powers AC, Johnson DB (2021) Endocrine toxicities of immune checkpoint inhibitors. Nat Rev Endocrinol 17(7):389\u2013399. https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat Rev Endocrinol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04659-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04659-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T13:17:26Z","timestamp":1690463846000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04659-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,4]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["4659"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04659-5","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,4]]},"assertion":[{"value":"2 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not disclosed any competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}